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Estetrol (E4) is a natural human estrogen present at high concentrations during pregnancy.
Due to its high oral bioavailability and long plasma half-life, E4 is particularly suitable for
therapeutic applications. E4 acts as a selective estrogen receptor (ER) modulator, exerting
estrogenic actions on the endometrium or the central nervous system, while antagonizing
the actions of estradiol in the breast. We tested the effects of E4 on its own or in the
presence of 17β-estradiol (E2) on T47-D ER+ breast cancer cell migration and invasion of
three-dimensional matrices. E4 administration to T47-D cells weakly stimulated migration
and invasion. However, E4 decreased the extent of movement and invasion induced by
E2. Breast cancer cell movement requires a remodeling of the actin cytoskeleton. During
exposure to E4, a weak, concentration-dependent, re-distribution of actin fibers toward
the cell membrane was observed. However, when E4 was added to E2, an inhibition of
actin remodeling induced by E2 was seen. Estrogens stimulate ER+ breast cancer cell
movement through the ezrin–radixin–moesin family of actin regulatory proteins, inducing
actin and cell membrane remodeling. E4 was a weak inducer of moesin phosphorylation
onThr558, which accounts for its functional activation. In co-treatment with E2, E4 blocked
the activation of this actin controller in a concentration-related fashion.These effects were
obtained through recruitment of estrogen receptor-α. In conclusion, E4 acted as a weak
estrogen on breast cancer cell cytoskeleton remodeling and movement. However, when
E2 was present, E4 counteracted the stimulatory actions of E2. This contributes to the
emerging hypothesis that E4 may be a naturally occurring ER modulator in the breast.
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INTRODUCTION
One out of eight women develops breast cancer at some stage
throughout life (1). Despite recent improvements in survival rates,
many patients relapse, and the majority dies for disseminated
metastatic disease.
In the mammary gland, estrogen promotes breast growth and
development at puberty and during the menstrual cycle and preg-
nancy (2). In addition to these physiological effects, estrogen plays
a major role in the development and progression of breast can-
cer. Prolonged exposure to estrogen, i.e., early menarche, late
menopause, or postmenopausal hormone therapy, is associated
with a greater risk of developing breast cancer (3). Estrogen pro-
motes breast cancer proliferation and tumor cell motility and
invasion through a number of established pathways (4).
Estetrol [estra-1,3,5(10)-triene-3,15α,16α,17β-tetrol] (E4) is
an estrogenic steroid produced by the human fetal liver dur-
ing pregnancy. Discovered by Diczfalusy in 1965 (5) and later
characterized by Gurpide (6), E4 is selectively synthesized during
pregnancy and is found in both fetal and maternal circulation (7–
9). Fetal blood concentration of E4 is 10–20-fold higher than the
maternal one (10). E4 has been recently developed for clinical use
in contraception and menopausal hormone replacement due to
its oral bioavailability and its minimal binding to sex hormone-
binding globulin. In addition, E4 has a slow elimination time and
long half-life, making it particularly suitable for once-a-day oral
therapies (11, 12).
E4 binds estrogen receptor-α (ERα) as well as ERβ (with a four-
fold lower affinity), and while it elicits estrogenic actions when
given alone, in several tissues it behaves as an anti-estrogen in the
presence of 17β-estradiol (13). This seems to be the case of the
breast, where E4 was found to reduce the growth of breast cancers
induced with a chemical carcinogen in rats, similar to tamox-
ifen (14). This raises the hypothesis that E4 may be a naturally
occurring selective estrogen receptor (ER) modulator.
Cell migration is required for cancer cell spread, invasion,
and metastasis and it is achieved through a dynamic remodel-
ing of filamentous actin and of focal adhesion sites (15). This
process leads to rapid changes of cell membrane morphology, with
the formation of specialized structures linked to cell movement
such as pseudopodia and ruffles (16). Estrogen administration to
breast cancer cells is associated with ERα membrane translocation
and with the rapid formation of such specialized cell membrane
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structures through the activation of the actin-binding protein,
moesin (17). Similar effects are found in endometrial cancer
cells (18), in human endothelial cells, where estrogen alters the
cytoskeleton and increases cell migration (19) as well as in neurons,
where this signaling pathway mediates the turnover of dendritic
spines (20). Moesin belongs to the ezrin–radixin–moesin (ERM)
family of actin-binding proteins (21). By interacting with actin,
activated ERMs induce actin de-polymerization and re-assembly
toward the cell membrane edge, supporting the formation of cor-
tical actin complexes (22). These complexes help the formation of
molecular bridges between the actin cytoskeleton, integrins, and
focal adhesion complexes within ruffles and pseudopodia and are
critical for cell movement in many settings, including breast cancer
progression and metastasis (16).
In this paper, we studied the effects of estetrol on migration
and invasion of ER+ breast cancer cells and we related these
observations to actin remodeling and to the activation of moesin,
characterizing the signaling steps involved in these actions.
MATERIALS AND METHODS
CELL CULTURES AND TREATMENTS
The human breast carcinoma cell line T47-D was obtained
from the American Type Culture Collection. T47-D cells were
grown in RPMI 1640 supplemented with l-glutamine (2 mM),
10% fetal bovine serum. Human umbilical vein endothelial cells
(HUVEC) were harvested enzymatically with type I A collage-
nase (1 mg/mL) and maintained in phenol red-free DMEM (Life
Technologies, Inc., Gaithersburg, MD, USA), containing HEPES
(25 mmol/L), heparin (50 U/mL), endothelial cell growth factor
(50 ng/mL), l-glutamine (2 mmol/L), antibiotics, and 10% FBS.
Before treatments, breast cancer and endothelial cells were kept
24 h in medium containing steroid-deprived FBS. Before experi-
ments investigating non-transcriptional effects, cells were kept in
medium containing no FBS for 8 h. Whenever an inhibitor was
used, the compound was added 30 min before starting the treat-
ments. 17β-estradiol was from Sigma-Aldrich (Saint-Louis, MO,
USA), ICI 182,780 was obtained by Tocris Cookson (Avonmouth,
UK). Estetrol was kindly provided by Herjian Coelingh Bennink,
Pantarhei Biosciences, The Netherlands.
IMMUNOBLOTTINGS
Cell lysates were separated by SDS-PAGE. Antibodies used were:
moesin (clone 38, Transduction Laboratories, Lexington, KY,
USA), Thr558-P-moesin (sc-12895, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), ERβ (sc-390243, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). Primary and secondary Abs were
incubated with standard technique. Immunodetection was accom-
plished with enhanced chemiluminescence. Intensity of the bands
was quantified with the NIH Image program on at least three
independent experiments.
GENE SILENCING WITH RNA INTERFERENCE
Synthetic small interfering RNAs targeting ER β (sc-35325, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) were used at the final
concentration of 100 nM to silence ERβ according to the manu-
facturer’s instructions. T47-D cells were treated 48 h after siRNA
transfection. The efficacy of gene silencing was checked with
western analysis and found to be optimal at 48 h.
CELL IMMUNOFLUORESCENCE
T47-D cells were grown on coverslips and exposed to treat-
ments. Cells were fixed and permeabilized with methanol at
−20°C for 10 min. Blocking was performed with 3% normal
serum for 20 min. Cells were incubated with Texas Red-phalloidin
(Sigma). Nuclei were counterstained with or 4′-6-diamidino-
2-phenylindole (DAPI) (Sigma) and mounted with Vectashield
mounting medium (Vector Laboratories, Burlingame, CA, USA).
Immunofluorescence was visualized using an Olympus BX41
microscope and recorded with a high-resolution DP70 Olym-
pus digital camera. After conversion to gray scale images, the
cell membrane thickness and the gray levels of the extracellular
area, cell membrane as well as cytoplasm were quantified using
the Leica QWin image analysis and image processing software
(Leica Microsystems, Wetzlar, Germany). Fifty cells per condition
were used, by measuring a 40 pixel distance encompassing the
extracellular space, the full thickness of the membrane, and the
intracellular space. Five separate measures were taken in each cell.
CELL MIGRATION ASSAY
Cell migration was assayed with razor scrape assays. Briefly, a
razor blade was pressed through the confluent cell monolayer
into the plastic plate to mark the starting line. Cells were swept
away on one side of that line. Cells were washed, and 2.0 mL of
medium containing steroid-deprived FBS and gelatin (1 mg/mL)
(to endothelial cells) were added. Cytosine β-d-arabinofuranoside
hydrochloride (Sigma) (10µM), a selective inhibitor of DNA syn-
thesis, which does not inhibit RNA synthesis was used 1 h before
the test substance was added to prevent cell proliferation. Absence
of cell proliferation and viability of the cells were checked in pre-
liminary experiments with MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] tests. Migration was monitored
for 48 h. Every 12 h, fresh medium and treatment were replaced.
Cells were digitally imaged and migration distance and num-
ber of cells migrating over the start line was measured by using
phase-contrast microscopy.
CELL INVASION ASSAY
Cell invasion were assayed using the BD BioCoat™ growth fac-
tor reduced (GFR) Matrigel™ Invasion Chamber (BD Bioscience,
USA). In brief, after rehydrating the GFR Matrigel inserts, the
test substance was added to the wells. An equal number of con-
trol inserts (no GFR Matrigel coating) were prepared as control.
0.5 mL of T47-D cell suspension (2.5× 104 cells/mL) was added to
the inner part of the inserts. The chambers were incubated for 24 h
at 37°C, 5% CO2 atmosphere. After incubation, the non-invading
cells were removed from the upper surface of the membrane using
cotton-tipped swabs. Then the cells on the lower surface of the
membrane were stained with Diff-Quick stain. The invading cells
were observed and photographed under the microscope at 100×
magnification. Cells were counted in the central field of triplicate
membranes. The invasion index was calculated as the % invasion
test cell/% invasion control cell.
STATISTICAL ANALYSIS
All values are expressed as mean± SD. Statistical differences
between mean values were determined by ANOVA, followed by
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the Fisher’s protected least significance difference (PLSD) with
version 12 of the SPSS software package (SPSS Inc., IL, USA). A
value of p< 0.05 was considered significant.
RESULTS
E4 CONTROLS ER+ BREAST CANCER CELL MIGRATION
Estrogen receptor agonists are able to enhance the ability of ER+
breast cancer cells to migrate in the surrounding environment. We
tested if E4 administration to T47-D cells turned into modified
horizontal migration of these cells. T47-D cells were seeded in
culture dishes. When confluent, a part of the cells were scraped
away with a razor blade. The extent of migration of the scraped
area of the dish by the remaining cells was monitored for 48 h in
cells that were treated with vehicle, E4, E2, or the combination of
the steroids. To control for potential effects on cell proliferation,
T47-D cells were pre-treated with cytosine β-d-arabinofuranoside
hydrochloride, an inhibitor of DNA synthesis that does not block
RNA synthesis.
As expected, E2 significantly increased breast cancer cell hor-
izontal migration (Figures 1A,B). When compared to E2, E4
displayed a much lower and yet concentration-related stimulatory
effect on horizontal cell migration (Figures 1A,B). When increas-
ing amounts of E4 were added to E2, the pro-migratory effects of
E2 were blunted in a fashion related to the concentration of E4
(Figures 1A,B).
With the aim to assess whether the effect of E4 on horizontal
migration may be limited to breast cancer cells, we performed
similar experiments in cultured HUVEC, where estrogens are
established activators of cell motility. E4 displayed a similar set
of actions also in HUVEC, as shown in Figures 1C,D.
E4 EFFECTS ON ER+ BREAST CANCER CELL INVASION
Analysis of the invasion of three-dimensional matrices is a useful
experimental system to assess the ability of cancer cells to progress
in complex environments, mimicking local progression. T47-D
cells treated with increasing concentrations of E4 showed slightly
increased matrigel invasion (Figures 2A,B). Similar to the find-
ings on horizontal migration, when E4 and E2 were administered
together, a decreased invasion as compared to what seen with E2
alone was found (Figures 2A,B).
E4 MODULATES ACTIN CYTOSKELETON REMODELING
Cell movement and invasion of the extracellular matrix depend on
the ability of cells to remodel their actin cytoskeleton. This process
allows for actin re-distribution toward the cell membrane, where it
supports the re-shaping of the membrane itself to form structures
such as ruffles and pseudopodia where adhesions with extracellu-
lar proteins or other cells can be formed. This basic set of events is
key to the activation of cell movement. To assess if the effects of E4
on horizontal movement or three-dimensional invasion of matri-
ces may be linked to structural cytoskeletal changes, we studied
the morphology and intracellular localization of actin fibers upon
administration of E4. Control cells displayed mainly longitudi-
nally arranged actin fibers in the cytoplasm (Figure 3). Addition
of E4 resulted in a rapid change in actin organization, with a
remodeling of the fibers toward the cell membrane edge, as shown
FIGURE 1 | Estetrol regulatesT47-D cell horizontal migration.
Steroid-deprived, growth synchronized ER+T47-D cells (A,B) or human
umbilical vein endothelial cells (HUVEC) (C,D) were exposed to 10−9 M E2
or to increasing concentrations of E4, or to the combination of the
steroids. Cells were scraped from the culture dish and the number of cells
migrated over the start line was assayed after 48 h. (A,C) Representative
images from triplicate experiments are shown. (B,D) Graphical
representations of the mean number of migrated cells ± SD are provided.
Quantification was obtained by pooling the results from three separate
experiments. In each experiments, 10 random microscopical fields were
selected and the number of migrated cells was assessed. *p<0.05 vs.
control. **p<0.05 vs. E2.
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FIGURE 2 | Estetrol regulates ER+ breast cancer cell invasion of
three-dimensional matrices. Steroid-deprived, growth synchronized ER+
T47-D cells were exposed to 10−9 M E2 or to increasing concentrations of E4,
or to the combination of the steroids. Breast cancer cell invasion through
matrigel was assayed by using invasion chambers. Invading cells were
counted in the central field of triplicate membranes. (A) Representative
images in chambers with matrigel are shown. (B) A graphical representation
of the invasion indexes in the different conditions is provided. Quantification
was obtained by pooling the results from three separate experiments. In each
experiments, 10 random microscopical fields were selected and the number
of invading cells counted. Invasion indexes were calculated as detailed in the
Section “Materials and Methods.” *p<0.05 vs. control. **p< 0.05 vs. E2.
by increased intensity of actin staining at the membrane and
increase membrane/cytosol actin staining intensity. Plus, exposure
to E4 was associated with the formation of specialized membrane
structures linked to cell attachment to the extracellular matrix
and to cell movement, such as pseudopodia and membrane ruf-
fles (Figure 3). The intensity of these changes was related to the
concentration of E4, with low E4 amounts being associated with
minimal effects and high concentrations of this steroid inducing
morphological changes that were comparable to those induced by
follicular phase concentrations of E2 (Figure 3).
When increasing amounts of E4 were added to a fixed concen-
tration of E2, inhibition of the E2-related actin remodeling was
seen, with high amounts of E4 completely blunting the changes in
actin architecture induced by E2 (Figure 3).
E4 REGULATES MOESIN PHOSPHORYLATION VIA THE ACTIVATION OF
ESTROGEN RECEPTOR IN BREAST CANCER CELLS
To check how E4 alters breast cancer cell’s actin dynamics, move-
ment, and invasion, we checked if E4 might interfere with estab-
lished signaling pathways controlled by ERs. Specifically, we looked
into possible regulatory actions of E4 on the actin regulatory mole-
cule, moesin, which is responsible in breast cancer cells for actin re-
shaping during cell movement. Thr558-moesin phosphorylation,
which corresponds to functional activation, was increased during
exposure to E4 and related to the concentration and the dura-
tion of exposure (Figures 4A,C). High amounts of E4 turned
into an enhancement of moesin phosphorylation similar to what
happens in the presence of follicular phase amounts of estradiol
(E2) (Figure 4A). Increased phosphorylation of moesin happened
rapidly upon administration of E4 or E2, occurring between 5 and
10 min after the administration of the compound (Figure 4C).
In parallel, administration of E4 to cells exposed to E2 resulted
into a near-complete and concentration-related blockade of the
E2-induced moesin phosphorylation (Figure 4B).
When ICI 182,780, a pure, non-selective ER antagonist (ICI,
1µM), was added along with E4 to T47-D cells, moesin phos-
phorylation was inhibited (Figure 4D), supporting the concept
that E4 signals in these cells by binding and modulating ERs.
Since Thr558-moesin phosphorylation in breast cancer cells is trig-
gered exclusively by ERα, we silenced the expression of ERβ in
T47-D cells with an siRNA system. Under these conditions, Thr558-
moesin phosphorylation was still seen notwithstanding a visible
decrease of ERβ expression (Figure 4E). This supports the hypoth-
esis that ERα may mediate in a privileged manner the actions of
E4 on moesin. This is also in line with the known higher affinity
of E4 for ERα.
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FIGURE 3 | Estetrol modulates the remodeling of the actin
cytoskeleton and of cell membrane inT47-D breast cancer cells.T47-D
cells were treated with E2 (10−9 M) or with different concentrations of E4,
or with a combination of the two steroids. Actin fibers were stained with
phalloidin linked to Texas Red (red labeling) and nuclei were counterstained
with DAPI (blue labeling). Immunofluorescent analysis reveals the dynamic
modifications of actin fibers through the time-course and the formation of
specialized cell membrane structures. Images are representative of
triplicate experiments. The box on top of the cells display sample areas of
measurement (one per cell, indicated as the yellow line), showing the
intensity of the signal throughout the measure. The results in the table are
derived from the sampling of five areas of the cell membrane from 50
different random cells. The areas of minimum and maximum cell
membrane thickness were always included. The results are the mean±SD
of the measurements. The graph plots the membrane/cytosol actin
intensity ratio. *p<0.05 vs. control. **p<0.05 vs. E2.
DISCUSSION
Estrogens act as promoters of cell proliferation and movement
in different tissues, including the breast (2). Estrogen receptor
positive (ER+) breast cancers are driven to grow, invade, and
metastasize by endogenous or exogenous estrogens (4, 23). For
these reasons, it is important to assess the effects of molecules with
estrogen-like activity on biological indicators of cancer cell pro-
gression. In this setting, estetrol emerges as an intriguing option.
While this steroid has been known since the 70s, the concept
of E4 as a potential treatment for humans has been proposed
only recently, hence reviving the interest for its clinical actions
(11, 14, 24–26).
The main finding of this study is that T47-D breast cancer cells
respond differently to E4 or E2 in terms of ability to diffuse in the
surrounding environment or to invade matrices. When exposed
to E2, these cells visibly enhance their invasive behavior starting
from physiological concentrations. On the opposite, exposure to
E4 does not elicit significant increases in motility or invasion if
not provided in high amounts, which is consistent with the results
of other studies (14).
From this set of results, and from the evidence that administer-
ing a pure ER antagonist prevents any action of E4, one may derive
that E4 acts as a highly selective but biologically weak ER-agonist.
This is clinically important, since it suggests that the spectrum of
desirable and undesirable effects of this steroid should fall within
the set of effects that have been widely characterized for E2 and
other estrogens. In other words, E4 use in humans would in prin-
ciple have a predictable risk/benefit profile. The safety of E4 is also
supported by the large production during pregnancy, when the
fetus is vulnerable to chemical and endocrine insults (10).
In our manuscript, we further demonstrate that E4 interferes
with the E2-associated actions in T47-D cells, suggesting that E4
may act as an endogenous selective estrogen receptor modula-
tor (SERM). This is consistent with recent results in rats, where
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FIGURE 4 | Estetrol modulates the activation of the actin-binding
protein, moesin. T47-D ER+ breast cancer cells were treated for
10 min with different amounts of E4, E2, or the combination
(A,B). Other cells were treated with E4 (10−7 M) for different times
(C). Lastly, T47-D cells were treated with E4 (10−7 M) in the presence or
absence of the pure ER antagonist ICI 182,780 (D) or of siRNAs toward
ERβ (E). Protein extracts were assayed with western analysis for their
overall content of wild type moesin (moesin), Thr558-phosphorylated
moesin (P-moesin), and ERβ. Images are representative of triplicate
experiments. The bar graphs show the mean±SD WB band intensity
out of the three independent experiments. *p<0.05 vs. control.
**p<0.05 vs. E2.
E4 blocks the E2-induced development and progression of breast
cancers as effectively as tamoxifen (14), and with the evidence
that this anti-estrogenic effect is paralleled by estrogenic activities
on tissues such as bone, vagina, myometrium, endometrium, and
brain (12, 24, 27).
From a mechanistic point of view, the present data points out
that E4 interferes with the estrogen-induced activation of proteins
regulating actin function and the remodeling of the cytoskeleton.
This set of actions is relevant for the development of special-
ized structures that mediate breast cancer cell interaction with
the extracellular matrix. Moesin activation in breast cancer cells
is the main established mediator of the estrogen-induced forma-
tion of pseudopodia and ruffles (16, 28). These actions represent a
ubiquitous effect of estrogens exerted by non-conventional activa-
tion of ERs at the cell membrane (29). Such actions are enacted by
estrogens to exert cell movement or remodeling in endothelial cells
(19), in endometrial cancer cells (18) as well as in neurons (20).
Actin remodeling is also a key process in cancer development.
Loss of stress fibers, represented by a re-distribution of actin fil-
aments from the cytoplasm toward the membrane, is one of the
early events in cancer cell transformation (30). Thus, cytoskeletal
rearrangement induced by estrogen through moesin may con-
tribute to the development of estrogen-sensitive breast cancers,
along with the enhanced metastatic behavior of such neoplasms
in the presence of sex steroid hormones (4). If this were true, the
ability of E4 to interfere with this process would be extremely
relevant in the clinical setting.
Even if these processes have been characterized related to the
ability of breast cancer cells to achieve movement, migration, and
invasion, their relevance may likely extend to the development
of tissues and organs that are sensitive to sex hormones, partic-
ularly during embryonic life. The finding that E4 may interfere
with E2 on such mechanisms could suggest that during pregnancy
this steroid may have a role in modulating the effects of the high
amounts of estrogens, preventing undesirable stimulatory effects
on the breast or other target tissues, both in the fetus and in the
mother.
The evidence that specific pathways that are related to breast
cancer progression are targeted by E4 opens the path to inves-
tigating whether this steroid may be used in women affected
by this disease as a new endocrine treatment. In this setting,
use of E4 would represent a particularly interesting concept,
given the absence of the side effects associated with all available
endocrine tools, such as tamoxifen, GnRH agonists, or aromatase
inhibitors. Potential conceptual application of this steroid based
on these estrogen-antagonizing effects may also be hormonal con-
traception or replacement in women with a history of breast
cancer.
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More in general, the opportunity to use a steroid that effectively
counteracts hot flushes, vulvo-vaginal atrophy, or osteoporosis
while protecting the breast would be a tremendous advancement
in menopausal medicine. From a clinical standpoint, fear of breast
cancer is the top reason for avoidance or discontinuation of hor-
mone replacement in postmenopausal women who may benefit
from these therapies. If future clinical trials will confirm that E4 is
endowed with breast-sparing effects in women, this steroid would
be a perfect candidate to help clinicians offer postmenopausal
hormone therapy to women when appropriate.
To this extent, this study carries a number of significant pitfalls.
While we find evidence of modulatory effects on T47-D cells of
E4, this may not extend to normal breast tissue or even to other
breast cancer cell lines. In addition, there are significant issues that
require additional investigation. For instance, it is not clear why
the addition of E4–E2 results in a blunting of the effects of E2.
Competitive inhibition of ERs may be an explanation, but other
mechanisms may also be involved, such as induction of a shift
away from the membrane (where moesin phosphorylation cas-
cade is initiated) of significant populations of ERs or alternatively
an increased internalization and destruction of ERs. This area is
important to understand the biological actions of E4 and will be
ground for future investigation.
In conclusion, this manuscript provides new information on
the effects of E4 on T47-D cells. E4 is a weak ER-agonist when
administered alone. However, E4 turns out to be a potent E2
antagonist when the two estrogens are provided together, reducing
the stimulatory effects of E2 on breast cancer cell cytoskele-
tal rearrangement, horizontal migration, and matrix invasion.
These results stimulate the interest on this long neglected steroid,
which seems to be characterized by an excellent clinical profile,
particularly for its potential breast safety.
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